The clinical manifestations of urogenital infections associated with SGLT2 inhibitors are extensive and various and their management depends on the type and severity of the infection, as well as on the context of the patients including comorbidities and other drugs taken simultaneously. This evidence concerns the gene SLC5A2 and infection.